Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.

Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

By weight-loss - Yahoo! News Search Results   //   Fitness Health Weight-loss News  //  Comments Off on Vivus Identifies Birth Defect Risk Tied to Weight-Loss Drug Qnexa

MOUNTAIN VIEW, Calif. (TheStreet) — The infants of women exposed during pregnancy to a component of Vivus’ weight-loss drug Qnexa had a higher rate of oral birth defects compared to infants not exposed to the drug during pregnancy, according to interim study results released Wednesday night. Vivus shares fell $1, or 9.6% to $9.40 in after-hours trading Wednesday. The drop in Vivus’ share price …

Comments are closed.